Trials / Completed
CompletedNCT02711969
A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment
A PhaseⅠStudy of Apatinib Mesylate (YN968D1) 1,000mg in Patients With Unresectable Locally Advanced or Metastatic Gastric Cancer Failed to Standard Therapy
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Bukwang Pharmaceutical · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
An open study to evaluate the safety of apatinib mesylate (YN968D1) 1,000mg monotherapy in patients with unresectable locally advanced or metastatic Gastric cancer failed to standard therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib mesylate | 1,000mg Apatinib mesylate p.o. qd |
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2016-11-01
- Completion
- 2019-03-01
- First posted
- 2016-03-17
- Last updated
- 2022-07-22
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02711969. Inclusion in this directory is not an endorsement.